Protara Therapeutics, Inc. (NasdaqGM: TARA)
Health Care · Biotechnology · US
$3.98
+3.38% today · +26.2% 1Y
Protara Therapeutics, Inc. (NasdaqGM: TARA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $227.52M and employs 46 people.
Over the last twelve months the share price has gained 26.2%, trading between 3.02 and 7.82.
Tweenvest scores Protara Therapeutics, Inc. across four factors: quality 28/100. Its strongest factor is quality.
TARA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $227.52M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.35
- Dividend yield
- —
- Beta (5Y)
- 1.49
- 52-week high
- $7.82
- 52-week low
- $3.02
- Avg volume (3M)
- —
- Shares outstanding
- 59.10M
- Employees
- 46
- Next earnings
- —
About Protara Therapeutics, Inc.
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
- ISIN
- US74365U1079
- Listed since
- Oct 22, 2014
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.00 | -0.19% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.32 | +1.08% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $157.82 | +13.63% |
Figures last refreshed Aug 18, 2026.